- UID
- 519788
- 在线时间
- 小时
- 注册时间
- 2010-3-17
- 最后登录
- 1970-1-1
- 主题
- 帖子
- 性别
- 保密
|
又是个二段论~ 5道题里面错了3题~ 看文章的结构倒不难, 第一段: F&M提出目前临床试验研究中需要改革; 段首即为主题句 第二段: F&M的改革建议的支持理由; 段首也是主题句 忍不住废话一下, 看看ETS的出题思路, 主旨题+细节题+推断题必出!
备注: 黄色高亮是主题句定位, 灰色高亮是细节题定位, 蓝色高亮是推断题定位,绿色字体是评价题定位
Frazier and Mosteller assert that medical research could be improved by a move toward larger, simpler clinical trials of medical treatments. Currently, researchers collect far more background (5)information on patients than is strictly required for their trials—substantially more than hospitals collect—thereby escalating costs of data collection, storage, and analysis. Although limiting information collection could increase the risk that (10) researchers will overlook facts relevant to a study, Frazier and Mosteller contend that such risk, never entirely eliminable from research, would still be small in most studies. Only in research on entirely new treatments are new and unexpected variables (15) likely to arise.
Frazier and Mosteller propose not only that researchers limit data collection on individual patients but also that researchers enroll more patients in clinical trials, thereby obtaining a more
(20) representative sample of the total population with the disease under study. Often researchers restrict study participation to patients who have no ailments besides those being studied. A treatment judged successful under these ideal conditions can (25) then be evaluated under normal conditions. Broadening the range of trial participants, Frazier and Mosteller suggest, would enable researchers to evaluate a treatment's efficacy for diverse patients under various conditions and to evaluate its (30) effectiveness for different patient subgroups.For example, the value of a treatment for a progressive disease may vary according to a patient's stage of disease. Patients' ages may also affect a treatment's efficacy. |
|
|